Early amniocentesis between 11 and 14 weeks' gestation was offered to 110 women at risk of a chromosomally abnormal fetus due to maternal age. Four were found to be unsuitable for the procedure, and 106 early amniocenteses were performed. In 102 cases, clear amniotic fluid was obtained with a single tap. There were two dry taps and two bloodstained taps; sampling was repeated in three of these cases before 15 weeks. In the fourth case, placental biopsy was performed at 16 weeks. Thus, we were able to obtain a satisfactory sample in all but three cases (2.8 per cent). Karyotyping of cells harvested from the early amniotic fluid samples was successful in all the 105 cases. Cell culture from the initial samples revealed a normal karyotype in 99 cases, two balanced translocations, two tetraploid karyotypes, and two cases of pseudomosaicism. Of the 105 pregnancies successfully sampled, there have been two losses to date (1.8 per cent). Two further patients presented with premature rupture of membranes, both pregnancies having successful outcomes. Sixty-two babies have delivered to date, with four congenital anomalies. There were no respiratory problems. Twenty-nine pregnancies are continuing without known complications, and details are not yet available on the remaining 12. The results indicate that early amniocentesis may replace the traditional test at 15-17 weeks.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pd.1970110506DOI Listing

Publication Analysis

Top Keywords

early amniocentesis
12
weeks' gestation
8
amniotic fluid
8
three cases
8
cases
6
early
5
amniocentesis 11-14
4
11-14 weeks'
4
gestation diagnosis
4
diagnosis fetal
4

Similar Publications

Background: Mucopolysaccharidosis type I (MPS I - IDUA gene) is a rare autosomal recessive lysosomal storage disorder. Clinical symptoms, including visceral overload, are progressive and typically begin postnatally. Descriptions of hepatosplenomegaly associated with lysosomal pathology are uncommon during the prenatal period.

View Article and Find Full Text PDF

Incidental Detection of Maternal Cancer Following Cell-Free DNA Screening for Fetal Aneuploidies.

Clin Chem

January 2025

Prenatal Genomics and Therapy Section, Center for Precision Health Research, National Human Genome Institute, National Institutes of Health, Bethesda, MD, United States.

Background: Prenatal cell-free DNA (cfDNA) screening is a success story of clinical genomics that has translated to and transformed obstetric care. It is a highly sensitive and specific method of screening for the most common fetal aneuploidies, including trisomies 13, 18, and 21. While primarily designed to detect fetal chromosomal abnormalities, the test also analyzes maternal cfDNA, which can complicate interpretation of results.

View Article and Find Full Text PDF

Indications of Amniocentesis and its Early and Late Complications.

Adv Biomed Res

October 2024

Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Background: Currently, it is recommended to arrange screening for all women who are referred for prenatal care before the 20 week of gestation. Congenital and genetic diseases lead to disability and death in 3% of babies. Prenatal diagnosis is the only way to prevent the birth of babies with genetic disorders.

View Article and Find Full Text PDF

Rationale: The aim of this study is to investigate the de novo mutation and clinical features of latent transforming growth factor-beta-binding protein 3 (LTBP3) gene-associated geleophysic dysplasia 3, and possible mechanisms of action.

Patient Concerns: A nonconsanguineous couple was recruited for this study due to the presence of intrauterine growth restriction. The pregnant woman and her elder daughter presented with skeletal abnormalities with diabetes.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aims to investigate the lipid profiles in early 2nd trimester amniotic fluid of healthy normal-weight mothers who have either large-for-gestational age (LGA) or appropriate-for-gestational age (AGA) infants, while also examining the relationship between lipid profiles and insulin/glucose levels.
  • - Researchers analyzed bio-banked amniotic fluid samples using advanced mass spectrometry techniques, comparing 15 LGA infants to 15 AGA infants and identified significant differences, including higher levels of specific phosphatidic acid species in LGA samples.
  • - The results suggest that even in healthy normal-weight mothers, there are early signs of disrupted lipid metabolism when carrying LGA infants, with no correlation found
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!